

UNIVERSITI TEKNOLOGI MARA

**INTERPATIENT VARIATION OF CLINICAL
RESPONSES AMONG ACUTE LYMPHOBLASTIC
LEUKAEMIA (ALL) PATIENTS TREATED WITH
6-MERCAPTOPYRIMIDINE (6-MP):
A PHARMACOGENOMICS - METABOLOMICS
PERSPECTIVE**

WAN ROSALINA WAN ROSLI

Thesis submitted in fulfilment of the requirements for the degree of
Doctor of Philosophy

Faculty of Pharmacy

July 2011

AUTHOR'S DECLARATION

I declare that the work in this thesis was carried out in accordance with the regulations of Universiti Teknologi MARA. It is original and is the result of my own work, unless otherwise indicated of knowledge as reference work. This thesis has not been submitted to any other academic institution or non-academic institution for any other degree or qualification.

I, hereby, acknowledge that I have been supplied with the Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.


Name of Student : Wan Rosalina Wan Rosli

Student I.D No. : 2006142555

Programme : Doctor of Philosophy (Pharmacy)

Faculty : Pharmacy

Thesis title : Understanding interpatient variation of clinical responses among acute lymphoblastic leukaemia (ALL) patients treated with 6-Mercaptopurine (6-MP): A Pharmacogenomics-Metabolomics Perspective

Signature of Student : 

Date : July 2011

ABSTRACT

Leukaemia chemotherapy had advanced considerably, enabling higher rates of survival and cure. This success is largely attributable to optimization of the use of chemotherapeutic agents such as 6-mercaptopurine (6-MP). However challenges still remain in striking a delicate balance between therapeutic outcome and risk of toxicity due to the narrow therapeutic window of anticancer drugs. This is compounded by the variability in patient response even when given the standard dose. Identification of patients at risk of adverse events would be beneficial, thus pharmacogenomics could play a role in reducing the related adverse drug reaction and hospitalization by the development of diagnostic tools to tailor appropriate therapies for patients. The aim of this study is to investigate the impact of pharmacogenomics in the clinical outcome of acute lymphoblastic leukaemia (ALL) patients that were on 6-MP. Therefore, 313 healthy Malaysian volunteers from each ethnic group (Malay, Chinese and Indians) and 63 ALL patients were recruited for the study and their blood sampled. The samples were then processed to obtain DNA, RNA and also metabolites. Investigations proceeded with the genotyping of *TPMT* common variants and *ITPA 94C>A* and the only *TPMT* common variant detected was heterozygous *TPMT*3C*. Whereas for *ITPA 94C>A* was detected at a high frequency, in accordance with other studies on Asian populations. There is higher likelihood of developing fever, liver toxicity and risk for relapse for ALL patients bearing the variant *ITPA 94A*. Variability in patient response was still observed therefore the patient samples were also subjected to denaturing high performance liquid chromatography (DHPLC) analysis to navigate the entire exon regions of *TPMT* for any variants other than the common variants assayed in PCR. There were a total of 15 variant sites detected that include both reported and unreported variations. Even though there is low frequency of *TPMT* common variants, the genotyping of other detected polymorphisms and haplotypes may prove more useful. Measurement of *TPMT* gene expression by absolute quantification of mRNA in patients' blood utilizing quantitative PCR (qPCR) was done for patient samples and found that the expression level was not uniform and this suggest that although there were no common variants of *TPMT* detected in patients, there may be other variants in the gene that affect the mRNA expression. Analyses have shown that there exist relationship between the DHPLC-detected variants and the variable level of *TPMT* expression. Global metabolite profiling of patient samples reveal that there exist differential expression among patients and healthy subjects as well as among patients with different genotype groups. Some metabolites detected such as glycerophosphocholine, hypoxanthine, linoleic acid metabolites and prostaglandin 2F alpha were previously associated with clinical outcome of cancer patients. At the end of study there were a total of nine metabolites that were identified to have potential to be used as biomarker either for disease progression, onset of adverse reaction and relapse. However the use of these metabolites in the clinical setting has to be validated further. An initial understanding of the biochemical processes that affect clinical outcome could aid in tailoring therapies that suit individual patient needs and be a positive step toward personalized medicine. At the end of this study establishment of the correlation between genotype, metabolite levels and *TPMT* expression with treatment outcome is hoped to lead to more effective therapy for patients in the future.

ACKNOWLEDGEMENT

Firstly I would like to express my gratitude to Allah s.w.t, for without Him nothing is possible. I would like to express my deepest appreciation and big thank you for my whole family, especially to my mother and father for their love, understanding and support.

Special -thanks to my supervisors; Prof Dr Mohd Zaki Salleh, Assoc Prof Dr Teh Lay Kek and Dr Rosmadi Mohd Yusoff for their help and guidance throughout this project. I would also like to extend my gratitude to all members of Pharmacogenomics Centre (PROMISE), UiTM for their continuous help and support.

I would like to extend my deepest appreciation to the research collaborators in Hospital Universiti Sains Malaysia (HUSM), Kelantan for their contributions to this research. Thank you to the Dean of Faculty of Pharmacy, UiTM for the opportunity to learn and be part of the faculty. Thank you to the Ministry of Science, Technology and Innovation (MOSTI) for scholarship and grants to pursue this research.

TABLE OF CONTENTS

CHAPTER 1

Research Background

1.1	Introduction	1
1.2	Literature review	3
1.2.1	Acute lymphoblastic leukaemia	3
1.2.2	The therapy and management of acute lymphoblastic leukaemia	4
1.2.3	Thiopurines	8
1.2.4	The mechanism of action of thiopurines	9
1.2.5	Thiopurine metabolism	9
1.2.6	Thiopurine methyltransferase (TPMT)	11
1.2.7	Inosine triphosphate pyrophosphohydrolase (ITPase)	16
1.2.8	Application of pharmacogenomics in cancer	18
1.2.9	Application of metabolomics in cancer	19
1.3	Statement of problem	20
1.4	Project objectives	21

CHAPTER 2

Materials and method

2.1	Overview of study	22
2.2	Chemicals, reagents and instruments	23
2.3	Subject recruitment and clinical data collection	23
2.3.1	Approval of ethics	23
2.3.2	Case Record Form (CRF) and Consent Form	23
2.3.3	Recruitment of healthy subjects	23
2.3.4	Recruitment of patients	24
2.3.5	Treatment protocol for patients	25
2.3.6	Definition of adverse events	26
2.3.7	Clinical data collection	29
2.3.8	Sample collection and storage	30
2.4	Sample preparation	31
2.4.1	Isolation of DNA	31
2.4.2	DNA extraction (manual extraction)	31
2.4.3	DNA extraction using QuickGene-810	32
2.4.4	Spectrophotometric determination of DNA concentration and purity	33
2.4.5	Determination of DNA integrity	35
2.4.6	Principles of RNA extraction	36
2.4.7	Blood sample RNA extraction	37
2.4.8	Determination of RNA concentration and integrity	39